COVID-19 treatment in elderly. Short Review

  • Vladislav Bezrukov D.F. Chebotarev Institute of Gerontology NAMS of Ukraine, Kiev
  • Liana Kuprash D.F. Chebotarev Institute of Gerontology NAMS of Ukraine, Kiev
  • Tetyana Panteleymonova D.F. Chebotarev Institute of Gerontology NAMS of Ukraine, Kiev
  • Olena Kuprash D.F. Chebotarev Institute of Gerontology NAMS of Ukraine, Kiev
  • Svetlana Gudarenko D.F. Chebotarev Institute of Gerontology NAMS of Ukraine, Kiev
Keywords: COVID-19; comorbid diseases; etiotropic agents; pathogenetic agents; symptomatic agents; complex therapy.

Abstract

Coronavirus SARS-CoV-2 disease (COVID-19) is characterized by severe and high mortality, which increases significantly with age. This poses a great threat to the elderly. The results of numerous clinical observations suggest that the interaction of drugs used in the COVID-19 treatment and concomitant pathology in elderly patients may worsen the course of the disease and lead to the development of serious complications. Therefore, a need for an individual approach to treatment. Appropriate adjustment of the doses of prescribed drugs and taking into account the interaction of drugs for the treatment of concomitant pathology will help to increase the effectiveness of COVID-19 drug therapy in the elderly.

Author Biographies

Vladislav Bezrukov, D.F. Chebotarev Institute of Gerontology NAMS of Ukraine, Kiev

MD, DSc (Medicine), Prof., Full Member (Academician) of the NAMS of Ukraine, Director of the D. F. Chebotarev Institute of Gerontology NAMS of Ukraine, Head of the Laboratory of Physiology

Liana Kuprash, D.F. Chebotarev Institute of Gerontology NAMS of Ukraine, Kiev

DSc (Medicine), Head of the Geriatric Pharmacology Laboratory

Tetyana Panteleymonova, D.F. Chebotarev Institute of Gerontology NAMS of Ukraine, Kiev

PhD (Biology), Leading Researcher of the Geriatric Pharmacology Laboratory

Olena Kuprash, D.F. Chebotarev Institute of Gerontology NAMS of Ukraine, Kiev

MD, PhD (Medicine), Department of Clinical and Epidemiological Cardiology

Svetlana Gudarenko, D.F. Chebotarev Institute of Gerontology NAMS of Ukraine, Kiev

Researcher of the Laboratory of Geriatric Pharmacology

References

Zhou, M.; Zhang, X.; Qu, J. Coronavirus disease 2019 (COVID-19): a clinical update. Front Med 2020, 14, 2, 126–135. https://doi.org/10.1007/s11684-020-0767-8

Bonanad, C.; Garcia-Blas, S.; Tarazona-Santabalbina, F.; Sanches, Ju.; Bertameu-Gonzales, V. et al. The Effect of Age on Mortality in Patients With COVID-19: A Meta-Analysis With 611,583 Subjects. J Am Med Dir Assoc 2020, 21, 7, 915–918. https://doi.org/10.1016/j.jamda.2020.05.045

Li, G.; Liu, Y.; Jing, X.; Wang, Ya.; Miao, M. et al. Mortality risk of COVID-19 in elderly males with comorbidities: a multi-country study. Aging (Albany NY) 2020, 13, 1, 27-60. https://doi.org/10.18632/aging.202456

Su, S.; Wong, G.; Shi, W. et al. Epidemiology, Genetic Recombination, and Pathogenesis of Coronaviruses. Trends Microbiol 2016, 24, 6, 490–502. https://doi.org/10.1016/j.tim.2016.03.003

Li, Ya-Ch.; Wai, W-Zh.; Hashikawa, Ts. The neurorvasive potencial of SARS-CoV-2 may the least partially responsible for the respiratory failure of COVID-19 patients. J Med Virol 2020, 92, 6, 552-555. https://doi.org/10.1002/jmv.25728

Zou, X.; Chen, K.; Zou, Ji.; Han, P.; Hao, Ji.; Han, Z. Sinyle-cell RNA-seq data analyses on the receptor ACE 2 expresion reveals the potential risk of different human organs vulnerable to 2019-nCoV infection. Front Med 2020, 14, 2, 185-192. https://doi.org/10.1007/s11684-020-0754-0

Channappanavar, R.; Perlman, S. Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology. Seminars Immunopathol 2017, 39, 5, 529–539. https://doi.org/10.1007/s00281-017-0629-x

Garnier‐Crussard, A.; Forestier, E.; Gilbert, T.; Krolak‐Salmon, P. Novel Coronavirus (COVID‐19) Epidemic: What Are the Risks for Older Patients? Am Geriatr Soc 2020, 68, 5, 939-940. https://doi.org/10.1111/jgs.16407

Khan, M.; Khan, H.; Khan, Sh.; Nawaz, M. Epidemiological and clinical characteristics of coronavirus disease (COVID-19) cases at a screening clinic during the early outbreak period: a single-centre study. J Med Biol 2020, 69, 8, 1114-1123. https://doi.org/10.1099/jmm.0.001231

Chen, N.; Zhou, M.; Dong, X. et al. (2020). Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 2020, 395, 10223, 507-513. https://doi.org/10.1016/s0140-6736(20)30211-7

Azkur, A. K.; Akdis, M.; Azkur, D. et al. Immune response to SARS‐CoV‐2 and mechanisms of immunopathological changes in COVID-19. Allergy 2020, 75, 7, 1564–1581. https://doi.org/10.1111/all.14364/

Connors, J. M.; Levy, J. H. COVID-19 and its implications for thrombosis and anticoagulation. Blood 2020, 135, 23, 2033-2040. https://doi.org/10.1182/blood.2020006000

Nikolich-Zugich J., Knox K. S., Rios C. T. et al. SARSCoV-2 and COVID-19 in Older Adults: What We May Expect Regarding Pathogenesis, Immune Responses, and Outcomes. Geroscience 2020, 42, 2, 505–514. https://doi. org/10.1007/s11357-020-00186-0

Landi, F.; Barillaro, C.; Bellieni, A.; Brandi, V.; Carfi, A. et al. The New Challenge of Geriatrics: Saving Frail Older People from the SARS-COV-2 Pandemic Infection. J Nutr Health Aging 2020, 24, 466–470. https://doi.org/10.1007/s12603-020-1356-x

Liu, Y.; Huang, F.; Xu, J. et al. Anti-hypertensive Angiotensin II receptor blockers an associated to mitigation of disease severity in elderly COVID-19 patients. medRxiv 2020, 20039586; https://doi.org/10.1101/ 2020.03.20.20039586

Niu, S.; Tian, S.; Lou, J.; Kang, X.; Zhang, L. et al. Clinical characteristics of older patients infected with COVID-19: a descriptive study. Arch Gerontol Geriatr 2020, 89, 104058. https://doi.org/10.1016/j.archger.2020.104058

Guo, T.; Shen, Q.; Guo, W.; Hi, W.; Li, Ji. et al. Clinical characteristics of elderly patients with COVID-19 in Hunan Province, China: a multicenter, retrospective study. Gerontology 2020, 66, 5, 467-475. https://doi.org/10.1159/000508734

Wang, L.; He, W.; Yu, X.; Hu, D.; Bao, M. et al. Coronavirus disease 2019 in elderly patients: characteristics and prognostic factors based on 4-week follow-up. J Infect 2020, 80, 6, 639-645. https://doi.org/10.1016/j.jinf.2020.03.019

Chen, T.; Dai, Z.; Mo, P.; Li, X.; Ma, Zh. et al. Clinical characteristics and outcomes of older patients with coronavirus disease 2019 (COVID-19) in Wuhan, China (2019): a single-centered, retrospective study. J Gerontol A Biol Sci Med Sci 2020, 16, 75, 9, 1788-1795. https://doi.org/10.1093/gerona/glaa089

Lian, J.; Jin, X.; Hao, S.; Cai, H.; Zhang, Sh. et al. Analysis of epidemiological and clinical features in older patients with coronavirus disease 2019 (COVID-19) out of Wuhan. Clin Infect Dis 2020, 71, 15, 740-747. https://doi.org/10.1093/cid/ciaa242

Huang, C.; Wang, Y.; Li, X.; Ren, L.; Zhao, J. et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020, 395, 10223, 497-506. https://doi.org/10.1016/s0140-6736(20)30183-5

Shahid, Z.; Kalayanamitra, R.; McClafferty, B. et al. COVID-19 and Older Adults: What We Know. J Am Geriatr Soc 2020, 68, 5, 926-929. https://doi.org/10.1111/jgs.16472

Solanki, T. Atypical Covid-19 presentations in older people – the need for continued vigilance. BGS England 2020. URL: https://www.bgs.org.uk/blog/atypical-covid-19-presentation-in-older-people-the-need-for-continued-vigilance

Gómez-Belda, A. B.; Fernández-Garcés, M.; Mateo-Sanchis, E.; Madrazo, M.; Garmona, M. et al. COVID-19 in older adults: What are the differences with younger patients? Geriatr Gerontol Int 2021, 21, 1, 60-65. https://doi.org/10.1111/ggi.14102

Liu, K.; Chen, Y.; Lin, R.; Han, K. Clinical feature of COVID-19 in elderly patients: a comparison with young and middle-aged patients. J Infect 2020, 80, 6, e14-e18. https://doi.org/10.1016/j.jinf.2020.03.005

Zhou, F.; Yu, T.; Du, R.; Fan, G.; Liu, Y. et al. (2020). Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020, 395, 10229, 1054-1062. https://doi.org/10.1016/s0140-6736(20)30566-3

Neumann-Podczaska, A.; Al-Saad, S. R.; Karbowski, L. M.; Chojnicki, M.; Tobis, S.; Wiecworowska- Tobis, K. COVID 19 - Clinical Picture in the Elderly Population: A Qualitative Systematic Review. Aging Dis 2020, 11, 4, 988-1008. https://doi.org/10.14336/ad.2020.0620

Arentz, M.; Yim, E.; Klaff, L.; Lokhandwala, Sh.; Riedo, F. X. et al. Characteristics and outcomes of 21 critically ill patients with COVID‐19 in Washington State. JAMA 2020, 323, 16, 1612-1614. https://doi.org/10.1001/jama.2020.4326

Wang, B.; Li, R.; Lu, Z. A.; Huang, Y. Does comorbidity increase the risk of patients with COVID-19: evidence from meta-analysis. Aging (Albany NY) 2020, 12, 7, 6049-6057. https://doi.org/10.18632/aging.103000

Goldman, J. D.; Lye, D. C. B.; Hui, D. S. et al. Remdesivir for 5 or 10 day in patient with severe COVID-19. Engl J Med 2000, 383, 19, 1827-1837. https://doi.org/10.1056/nejmoa2015301

Wang, Y.; Zhang, D.; Du, G. et al. Remdesivir in adults with severe COVID-19: a randomized, double-blind, placebo-controlled, multicenter trial. Lancet 2000, 395, 10236, 1569-1578. https://doi.org/10.1016/S0140-6736(20)31022-9

Beigel, J. H.; Tomashek, L. E.; Dodd, L. E. et al. Remdesivir for the treatment of COVID-19 - preliminary report. Engl J Med 2020, 383, 19, 1813-1826. https://doi.org/10.1056/nejmoa2007764

Jorgensen S.C.J. Kebriaei R., Dresser L.D. Remdesivir: Review of pharmacology, pre-clinical data, and emerging clinical experience for COVID-19. Pharmacotherapy 2020, 40, 7, 659-671. https://doi.org/10.1002/phar.2429

Cai, Q., Yang, M., Liu, D., Chen, J., Shu, D., Xia, J., & Shen, C. (2020). Experimental treatment with favipiravir for COVID-19: an open-label control study. Engineering (Beijing) 2020, 6, 10, 1192-1198. https://doi.org/10.1016/j.eng.2020.03.007

Yohei, D. Preliminary Report of the Favipiravir Observational Study in Japan. URL: http://www.kansensho.or.jp/uploads/files/topics/2019ncov/covid19_casereport_en_200529.pdf

Cortegiani, A.; Ingoglia, G.; Ippolito, M.; Giarratano, A. & Einav, S. A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19. Journal of Critical Care 2020, 57, 279-283. https://doi.org/10.1016/j.jcrc.2020.03.005

Mehra, M. R.; Desai, S. S.; Ruschitzka, F.; Patel, A. N. RETRACTED: Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis. Lancet 2020, S0140-6736, 2, 31180-31186. https://doi.org/10.1016/s0140-6736(20)31180-6

Huang, M.; Tang, T.; Pang, P.; Li, M.; Ma, R. et al. Treating COVID-19 with Chloroquine. J Mol Cell Biol 2020, 12, 4, 322-325. https://doi.org/10.1093/jmcb/mjaa014

Zhu, Z.; Lu, Z.; Xu, T.; Chen, C.; Yang, G. et al. Arbidol monotherapy is superior to lopinavir/ritonavir in treating COVID-19. J Infect 2020, 81, 1, e21-e23. https://doi.org/10.1016/j.jinf.2020.03.060

Deng, L.; Li, C.; Zeng, Q.; Liu, X.; Li, X. et al. Arbidol combined with LPV/r versus LPV/r alone against Corona Virus Disease 2019: A retrospective cohort study. J Infect 2020, 81, 1, e1-e5. https://doi.org/10.1016/j.jinf.2020.03.002

Driggin, E.; Madhavan, M. V.; Bikdeli, B. et al. Cardiovascular Considerations for Patients, Health Systems During the COVID-19 Pandemic. J Am Coll Card Mar 2020, 75, 18, 2352-2371

Gupta R., Ghosh A., Singh A.K. et al. Clinical Considerations for Patients with Diabetes in Times of COVID-19 Epidemic. Diabetes Metab Syndr 2020, 14, 3, 211-212. https://doi.org/10.1016/j.dsx.2020.03.002

Yang, J.; Zheng, Y.; Gou, X. et al. Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis. Int J Infect Dis 2020, 94, 91-95. https://doi.org/10.1016/j.ijid.2020.03.017

Zhang, P.; Zhu, L.; Cai, J. et al. Association of Inpatient Use of Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers with Mortality Among Patients with Hypertension Hospitalized With COVID-19. Circulation Research 2020, 126, 12, 1671-1681. https://doi.org/10.1161/circresaha.120.317134

Huang, M.; Tang, T.; Pang, P.; Li, M.; Ma, R. et al. Treating COVID-19 with Chloroquine. J Mol Cell Biol 2020, 12, 4, 322-325. https://doi.org/10.1093/jmcb/mjaa014

Zhu, Z.; Lu, Z.; Xu, T.; Chen, C.; Yang, G. et al. Arbidol monotherapy is superior to lopinavir/ritonavir in treating COVID-19. J Infect 2020, 81, 1, e21-e23. https://doi.org/10.1016/j.jinf.2020.03.060

Deng, L.; Li, C.; Zeng, Q.; Liu, X.; Li, X. et al. Arbidol combined with LPV/r versus LPV/r alone against Corona Virus Disease 2019: A retrospective cohort study. J Infect 2020, 81, 1, e1-e5. https://doi.org/10.1016/j.jinf.2020.03.002

Peng, F.; Tu, L.; Yang, Yo.; Hu, P.; Wang, R. et al. Management and Treatment of COVID-19: The Chinese Experience. Can J Cardiol 2020, 36, 6, 915-930. https://doi.org/10.1016/j.cjca.2020.04.010

ЕМА – Guidance on the Management of Clinical Trials during the COVID19 (Coronavirus) pandemic URL: https://ec.europa.eu/health/sites/health/ files/files/eudralex/vol-10/guidanceclinicaltrials_covid19_en.pdf

Pawelczyk, A.; Zaprutko, L. Anti-COVID drugs: repurposing existing drugs or search for new complex entities, strategies and perspectives. Future Med Chem 2020, 12, 19, 1743-1757. https://doi.org/10.4155/fmc-2020-0204

Wu, J.; Li, W.; Shi, X.; Chen, Z.; Jiang, B. et al. Early antiviral treatment contributes to alleviate the severity and improve the prognosis of patients with novel coronavirus disease (COVID-19). J Intern Med 2020, 288, 1, 128-138. https://doi.org/10.1111/joim.13063

Goldman, J. D.; Lye, D. C. B.; Hui, D. S. et al. Remdesivir for 5 or 10 day in patient with severe COVID-19. Engl J Med 2000, 383, 19, 1827-1837. https://doi.org/10.1056/nejmoa2015301

Wang, Y.; Zhang, D.; Du, G. et al. Remdesivir in adults with severe COVID-19: a randomized, double-blind, placebo-controlled, multicenter trial. Lancet 2000, 395, 10236, 1569-1578. https://doi.org/10.1016/S0140-6736(20)31022-9

Beigel, J. H.; Tomashek, L. E.; Dodd, L. E. et al. Remdesivir for the treatment of COVID-19 - preliminary report. Engl J Med 2020, 383, 19, 1813-1826. https://doi.org/10.1056/nejmoa2007764

Jorgensen S.C.J. Kebriaei R., Dresser L.D. Remdesivir: Review of pharmacology, pre-clinical data, and emerging clinical experience for COVID-19. Pharmacotherapy 2020, 40, 7, 659-671. https://doi.org/10.1002/phar.2429

Cai, Q., Yang, M., Liu, D., Chen, J., Shu, D., Xia, J., & Shen, C. (2020). Experimental treatment with favipiravir for COVID-19: an open-label control study. Engineering (Beijing) 2020, 6, 10, 1192-1198. https://doi.org/10.1016/j.eng.2020.03.007

Harch P. G. Hyperbaric oxygen treatment of novel coronavirus (COVID-19) respiratory failure. Med Gas Res 2020, 10, 2, 61–62. https://doi.org/10.4103/2045-9912.282177

Yohei, D. Preliminary Report of the Favipiravir Observational Study in Japan. URL: http://www.kansensho.or.jp/uploads/files/topics/2019ncov/covid19_casereport_en_200529.pdf

Cortegiani, A.; Ingoglia, G.; Ippolito, M.; Giarratano, A. & Einav, S. A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19. Journal of Critical Care 2020, 57, 279-283. https://doi.org/10.1016/j.jcrc.2020.03.005

Mehra, M. R.; Desai, S. S.; Ruschitzka, F.; Patel, A. N. RETRACTED: Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis. Lancet 2020, S0140-6736, 2, 31180-31186. https://doi.org/10.1016/s0140-6736(20)31180-6

Huang, M.; Tang, T.; Pang, P.; Li, M.; Ma, R. et al. Treating COVID-19 with Chloroquine. J Mol Cell Biol 2020, 12, 4, 322-325. https://doi.org/10.1093/jmcb/mjaa014

Zhu, Z.; Lu, Z.; Xu, T.; Chen, C.; Yang, G. et al. Arbidol monotherapy is superior to lopinavir/ritonavir in treating COVID-19. J Infect 2020, 81, 1, e21-e23. https://doi.org/10.1016/j.jinf.2020.03.060

Deng, L.; Li, C.; Zeng, Q.; Liu, X.; Li, X. et al. Arbidol combined with LPV/r versus LPV/r alone against Corona Virus Disease 2019: A retrospective cohort study. J Infect 2020, 81, 1, e1-e5. https://doi.org/10.1016/j.jinf.2020.03.002

Peng, F.; Tu, L.; Yang, Yo.; Hu, P.; Wang, R. et al. Management and Treatment of COVID-19: The Chinese Experience. Can J Cardiol 2020, 36, 6, 915-930. https://doi.org/10.1016/j.cjca.2020.04.01049.65

Antimicrobial Stewardship in COVID-19. 2020. URL: https://www.hpsc.ie/a-z/respiratory/coronavirus/novelcoronavirus/guidance/infectionpreventionandcontrolguidance/antimicrobialstewardship/Antimicrobial%20Stewardship%20in%20COVID%2019.pdf

Jiang, F.; Deng, L.; Zhang, L.; Cai, Y.; Cheung, C. W.; Xia, Z. Review of the clinical characteristics of coronavirus disease 2019 (COVID-19). J Gen Intern Med 2020, 35, 5, 1545-1549. https://doi.org/10.1007/s11606-020-05762-w

Villar, J.; Ferrando, C.; Martínez, D. et al. Dexamethasone treatment for the acute respiratory distress syndrome: a multicentre, randomised controlled trial. Lancet Respir Med 2020, 8, 3, 267-276. https://doi.org/10.1016/s2213-2600(19)30417-5

Jamilloux, Y.; Henry; T.; Belot, A. et al. Should we stimulate or suppress immune responses in COVID-19? Cytokine and anticytokine interventions. Autoimmun Rev 2020, 19, 7, 102567. https://doi.org/10.1016/j.autrev.2020.102567

Angus, D. C.; Derde, L.; Al-Beidh, F. et al. Effect of hydrocortisone on mortality and organ support in patients with severe COVID 19: The REMAP-CAP COVID 19 Corticosteroid Domain Randomized Clinical Trial. JAMA 2020, 324, 13, 1317-1329. https://doi.org/10.1001/jama.2020.17022

Horby, P.; Lim, W. S.; Emberson, J. R. et al. Dexamethasone in hospitalized patients with COVID-19. N Engl J Med 2021, 384, 8, 693-704. https://doi.org/10.1056/nejmoa2021436

Published
2022-07-21
How to Cite
Bezrukov, V., Kuprash, L., Panteleymonova, T., Kuprash, O., & Gudarenko, S. (2022). COVID-19 treatment in elderly. Short Review. Ageing and Longevity, 3(3), 77-85. Retrieved from http://aging-longevity.org.ua/index.php/journal-description/article/view/57
Section
Статьи